Leptin and adiponectin in patients with chronic kidney disease and secondary hyperparathyroidism

Authors

  • N. Karlovich Belarusian State Medical University, Minsk, Belarus
  • Т. Mokhort Belarusian State Medical University, Minsk, Belarus https://orcid.org/0000-0002-5040-3460
  • Е. Sazonоva Belarusian State Medical University, Minsk, Belarus; Republican Center of Medical Rehabilitation and Balneotherapy, Minsk, Belarus

DOI:

https://doi.org/10.22141/2224-0721.17.8.2021.246790

Keywords:

adiponectin, leptin, chronic kidney disease, secondary hyperparathyroidism

Abstract

Background. The results of studies evaluating the levels of adiponectin, leptin and their ratios in chronic kidney disease (CKD) are conflicting. It is assumed that hyperleptinemia and changes in adiponectin clearance are consequences of a decrease in the glomerular filtration rate, they exacerbate renal impairment and may affect the prognosis of survival due to cardiovascular events. It is known that secondary hyperaparathyroidism is the most frequent complication of CKD, which not only affects calcium-phosphorus metabolism and bone tissue, but also contributes to the development of pathological processes involving other hormonal and metabolic markers. Of greatest interest is the assessment of adipocytokine levels in the development of secondary hyperparathyroidism against the background of CKD as an independent factor of increasing cardiovascular risks. The purpose of the study was to assess adipocytokine levels (adiponectin, leptin) and their ratios in patients with different stages of chronic kidney disease and their relationship with manifestations of secondary hyperparathyroidism. Materials and methods. This cross-sectional study enrolled 160 people with CKD and 40 healthy individuals as a comparison group. Results. Leptin level reduction and an increase in the proportion of patients with hypoleptinemia with a decrease in the glomerular filtration rate were found, which may be an important factor determining nutritional status. Correlations were revealed between leptin level, body mass index (ρ = 0.411) and patients’ age (ρ = 0.189), as well as between leptin/adiponectin and adiponectin/leptin ratios (ρ = 0.395 and ρ = –0.395) and body mass index in patients with CKD persisting in subgroups by stage of renal failure. A relationship was found with sex for leptin and a decrease in its levels below normal values in both men and women. Conclusions. The proportion of patients with hyperadiponectinemia was significantly higher among those with end-stage CKD compared to patients with stages 1–2. There was no statistically significant relationship between adipocytokine and parathyroid hormone levels and the presence of secondary hyperparathyroidism in patients examined.

Downloads

Download data is not yet available.

References

Frühbeck G, Catalán V, Rodríguez A, Gómez-Ambrosi J. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte. 2018 Jan 2;7(1):57-62. doi: 10.1080/21623945.2017.1402151.

GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362.

Lim CC, Teo BW, Tai ES, et al. Elevated serum leptin, adiponectin and leptin to adiponectin ratio is associated with chronic kidney disease in Asian adults. PLoS One. 2015 Mar 20;10(3):e0122009. doi: 10.1371/journal.pone.0122009.

Wannamethee SG, Tchernova J, Whincup P, et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007 Apr;191(2):418-26. doi: 10.1016/j.atherosclerosis.2006.04.012.

Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003 Jan 18;361(9353):226-8. doi: 10.1016/S0140-6736(03)12255-6.

Lee KW, Shin D. Prospective Associations of Serum Adiponectin, Leptin, and Leptin-Adiponectin Ratio with Incidence of Metabolic Syndrome: The Korean Genome and Epidemiology Study. Int J Environ Res Public Health. 2020 May 8;17(9):3287. doi: 10.3390/ijerph17093287.

Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res. 2009 Nov-Dec;37(6):1803-12. doi: 10.1177/147323000903700616.

Alnaggar ARLR, Sayed M, El-Deena KE, Gomaa M, Hamed Y. Evaluation of serum adiponectin levels in diabetic nephropathy. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):128-131. doi: 10.1016/j.dsx.2018.04.035.

Hyun YY, Lee KB, Oh KH, et al; Representing KNOW-CKD Study Group. Serum adiponectin and protein-energy wasting in predialysis chronic kidney disease. Nutrition. 2017 Jan;33:254-260. doi: 10.1016/j.nut.2016.06.014.

Karlovich NV, Mohort TV. Secondary hyperparathyroidism in chronic kidney disease: monograph. Minsk: UO BSMU; 2021. 177 p. (in Russian).

Levey AS, Coresh J, Greene T, et al; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006 Aug 15;145(4):247-54. doi: 10.7326/0003-4819-145-4-200608150-00004.

Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4;158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040-00007.

Sprent P. Statistics in medical research. Swiss Med Wkly. 2003 Oct 11;133(39-40):522-9.

Shankar A, Syamala S, Xiao J, Muntner P. Relationship between Plasma Leptin Level and Chronic Kidney Disease. Int J Nephrol. 2012;2012:269532. doi: 10.1155/2012/269532.

Karlovich NV, Spiridonova OS, Sazonova EG, Mokhort TV. Determination of the parathyroid hormone reference interval in patients with different stages of the chronic kidney disease. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2021;18(2):186-195. (In Russian). doi: 10.29235/1814-6023-2021-18-2-186-195.

Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.

Fang H, Judd RL. Adiponectin Regulation and Function. Compr Physiol. 2018 Jun 18;8(3):1031-1063. doi: 10.1002/cphy.c170046.

Vasilkova O, Mokhort T, Naumenko E, Korotayeva L, Filiptsova N. Insulin-Like Growth Factor-1 and Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. International Journal of Endocrinology (Ukraine). 2019;15(1):3-9. doi: 10.22141/2224-0721.15.1.2019.158685.

Zhang J, Wang N. Leptin in chronic kidney disease: a link between hematopoiesis, bone metabolism, and nutrition. Int Urol Nephrol. 2014 Jun;46(6):1169-74. doi: 10.1007/s11255-013-0623-8.

Jiang Y, Shen Z, Zhang J, et al. Parathyroidectomy Increases Heart Rate Variability and Leptin Levels in Patients with Stage 5 Chronic Kidney Disease. Am J Nephrol. 2016;44(3):245-54. doi: 10.1159/000449018.

Published

2022-02-23

How to Cite

Karlovich, N., Mokhort Т., & Sazonоva Е. (2022). Leptin and adiponectin in patients with chronic kidney disease and secondary hyperparathyroidism. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 17(8), 596–603. https://doi.org/10.22141/2224-0721.17.8.2021.246790

Issue

Section

Original Researches